Literature DB >> 12942352

Multifactorial assessment of predictors for prevention of periodontal disease progression.

Benjamin Ehmke1, Thomas Beikler, Imme Haubitz, Helge Karch, Thomas Frank Flemmig.   

Abstract

Univariate approaches have identified single factors influencing periodontal disease progression. The aim of this explorative approach was to assess the influence of various predictive factors responsible for the prevention of periodontal disease progression in the same patient sample. Patients with untreated chronic periodontitis underwent subgingival debridement alone or in combination with adjunctive antimicrobial therapy (systemic amoxicillin and metronidazole/7 days plus supragingival CHX irrigation). Supportive periodontal therapy was performed over a 24-month period. As predictors, clinical, microbial, immunological, and genetic parameters were assessed. The primary outcome variable was the percentage of teeth without attachment loss >/=2 mm over the study period (stability of attachment). At 24 months, multiple regression analysis identified adjunctive antimicrobial therapy for teeth with initially at least one site showing a pocket probing depth of >/=7 mm and IgG(4) reactivity against a 110-kDa protein of A. actinomycetemcomitans at teeth with initial pocket probing depths </=6 mm as main predictors of long-term attachment stability ( p<0.05). Other parameters failed to influence treatment outcome. Adjunctive antimicrobial therapy and antibody reactivity may be dominant factors influencing the prevention of attachment loss in patients receiving periodontal therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12942352     DOI: 10.1007/s00784-003-0227-2

Source DB:  PubMed          Journal:  Clin Oral Investig        ISSN: 1432-6981            Impact factor:   3.573


  29 in total

Review 1.  Ecological considerations in the treatment of Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis periodontal infections.

Authors:  S S Socransky; A D Haffajee; L A Ximenez-Fyvie; M Feres; D Mager
Journal:  Periodontol 2000       Date:  1999-06       Impact factor: 7.589

2.  Simultaneous detection of Bacteroides forsythus and Prevotella intermedia by 16S rRNA gene-directed multiplex PCR.

Authors:  G Conrads; T F Flemmig; I Seyfarth; F Lampert; R Lütticken
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

Review 3.  Systemic antibiotics in the treatment of periodontal disease.

Authors:  Jørgen Slots; Miriam Ting
Journal:  Periodontol 2000       Date:  2002       Impact factor: 7.589

4.  Comparison of measurement variability in subjects with moderate periodontitis using a conventional and constant force periodontal probe.

Authors:  J B Osborn; J L Stoltenberg; B A Huso; D M Aeppli; B L Pihlstrom
Journal:  J Periodontol       Date:  1992-04       Impact factor: 6.993

5.  The use of metronidazole and amoxicillin in the treatment of advanced periodontal disease. A prospective, controlled clinical trial.

Authors:  T Berglundh; L Krok; B Liljenberg; E Westfelt; G Serino; J Lindhe
Journal:  J Clin Periodontol       Date:  1998-05       Impact factor: 8.728

6.  Relationship of serum antibody to attachment level patterns in young adults with juvenile periodontitis or generalized severe periodontitis.

Authors:  J C Gunsolley; J A Burmeister; J G Tew; A M Best; R R Ranney
Journal:  J Periodontol       Date:  1987-05       Impact factor: 6.993

7.  Identification of Actinobacillus actinomycetemcomitans in subgingival plaque by PCR.

Authors:  T F Flemmig; S Rüdiger; U Hofmann; H Schmidt; B Plaschke; A Strätz; B Klaiber; H Karch
Journal:  J Clin Microbiol       Date:  1995-12       Impact factor: 5.948

8.  Antibody reactive with Actinobacillus actinomycetemcomitans leukotoxin in early-onset periodontitis patients.

Authors:  J V Califano; B E Pace; J C Gunsolley; H A Schenkein; E T Lally; J G Tew
Journal:  Oral Microbiol Immunol       Date:  1997-02

9.  Serum antibody reactivity against recombinant PrtC of Porphyromonas gingivalis following periodontal therapy.

Authors:  T Beikler; B Ehmke; M Wittstock; H Schmidt; H Karch; T F Flemmig
Journal:  J Periodontal Res       Date:  2003-06       Impact factor: 4.419

10.  Differential clinical treatment outcome after systemic metronidazole and amoxicillin in patients harboring Actinobacillus actinomycetemcomitans and/or Porphyromonas gingivalis.

Authors:  T F Flemmig; E Milián; H Karch; B Klaiber
Journal:  J Clin Periodontol       Date:  1998-05       Impact factor: 8.728

View more
  5 in total

1.  Intraoral dissemination of treponemes after periodontal therapy.

Authors:  Benjamin Ehmke; Thomas Beikler; Birgit Riep; Thomas Flemmig; Ulf Göbel; Annette Moter
Journal:  Clin Oral Investig       Date:  2004-06-23       Impact factor: 3.573

2.  Tracking of plasma antibodies against Aggregatibacter actinomycetemcomitans and Porphyromonas gingivalis during 15 years.

Authors:  Laura Lakio; Johanna Antinheimo; Susanna Paju; Kåre Buhlin; Pirkko J Pussinen; Georg Alfthan
Journal:  J Oral Microbiol       Date:  2009-08-03       Impact factor: 5.474

Review 3.  An estimate of pocket closure and avoided needs of surgery after scaling and root planing with systemic antibiotics: a systematic review.

Authors:  Mirela Kolakovic; Ulrike Held; Patrick R Schmidlin; Philipp Sahrmann
Journal:  BMC Oral Health       Date:  2014-12-22       Impact factor: 2.757

Review 4.  Influence of different post-interventional maintenance concepts on periodontal outcomes: an evaluation of three systematic reviews.

Authors:  Stefanie J Gartenmann; Iris Dörig; Philipp Sahrmann; Ulrike Held; Clemens Walter; Patrick R Schmidlin
Journal:  BMC Oral Health       Date:  2016-07-18       Impact factor: 2.757

Review 5.  The concomitant administration of systemic amoxicillin and metronidazole compared to scaling and root planing alone in treating periodontitis: =a systematic review=.

Authors:  Dina Zandbergen; Dagmar Else Slot; Richard Niederman; Fridus A Van der Weijden
Journal:  BMC Oral Health       Date:  2016-02-29       Impact factor: 2.757

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.